Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
- 12 April 2022
- journal article
- review article
- Published by Wiley in Hepatology Research
- Vol. 52 (6) , 497-507
Abstract
Liver fibrosis is the most important prognostic factor in patients with nonalcoholic fatty liver disease (NAFLD). Several noninvasive markers for fibrosis, including blood‐based markers and imaging based‐markers have been developed. Indirect fibrosis markers (e.g., fibrosis‐4 index and NAFLD fibrosis score) consist of standard laboratory data and clinical parameters. Given its availability and high negative predictive value for advanced fibrosis, these markers are suitable for screening at primary care. Blood‐based fibrogenesis markers (enhanced liver fibrosis and N‐terminal propeptide of type 3 collagen), ultrasound‐based modalities (vibration‐controlled transient elastography, point shear wave elastography [SWE], and two‐dimensional SWE), and magnetic resonance elastography have high diagnostic accuracy for liver fibrosis and are suitable for diagnosing liver fibrosis at secondary care centers. Sequential use of these markers can increase diagnostic accuracy and reduce health care costs. Furthermore, combining noninvasive makers may assist in identifying candidates for pharmacological trials and reducing screening failure. Emerging data suggest that these noninvasive markers are associated with liver‐related events (hepatocellular carcinoma and decompensation) and mortality. Furthermore, delta change in noninvasive markers over time is also associated with time‐course change in fibrosis, liver‐related event risk, and mortality risk. However, the association between liver fibrosis and cardiovascular disease (CVD) risk is still controversial. CVD risk may decrease in patients with decompensated liver disease and noninvasive markers may be useful for assessing CVD risk in these patients. Therefore, noninvasive markers may be utilized as measures of fibrosis as well as real‐time prognostic tools, in place of liver biopsy.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK120515, R01DK106419, R01DK121378, R01DK124318, U01DK061734, U01DK130190)
- National Center for Advancing Translational Sciences (5UL1TR001442)
- Japan Agency for Medical Research and Development (22fk0210072s0203, JP20fk0210067h0001)
- National Institute on Alcohol Abuse and Alcoholism (U01AA029019)
- National Heart, Lung, and Blood Institute (P01HL147835)
This publication has 119 references indexed in Scilit:
- A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitisScientific Reports, 2013
- Noninvasive estimation of fibrosis progression overtime using the FIB‐4 index in chronic hepatitis CJournal of Viral Hepatitis, 2012
- Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease populationBMC Gastroenterology, 2012
- Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infectionLiver International, 2009
- External validation of FIB-4: Diagnostic accuracy is limited in elderly populationsHepatology, 2007
- Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stageJournal of Gastroenterology, 2007
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Serum Propeptides of Type I and III Procollagens in Renal Transplant RecipientsNephron, 1994